Earlier this summer, Pfizer halted global distribution of its smoking cessation drug, Chantix. A few weeks later, the company recalled over a dozen lots of the drug. Now, according to a Fierce Pharma article, the drugmaker is recalling all 0.5 mg and 1 mg lots across the country. The reason is the the drug was found to contain unacceptable levels of a specific nitrosamine, which can cause cancer over time with exposure to high levels. The drug was approved by the FDA 15 years ago, and saw nearly a billion in sales last year.
Pfizer Recalls All Chantix Nationwide
The recall is a precautionary measure taken after the medicine was found to contain a cancer-causing impurity.
Sep 23, 2021
Recommended
Recommended
Pharmaceutical Innovations Report
Discover the latest breakthrough packaging technologies shaping the pharmaceutical sector. This report dives into cutting-edge innovations, from smart containers that enhance patient safety to eco-friendly materials poised to transform the industry’s sustainability practices. All from PACK EXPO. Learn how forward-thinking strategies are driving efficiency and redefining what’s possible in pharma packaging.
Learn More
Break out of the ordinary: see what’s new in life sciences packaging
At PACK EXPO Las Vegas, you’ll see machinery in action and new tech from 2,300 suppliers, collaborate with experts and explore transformative solutions. Join us this month to experience a breakthrough for life sciences products.
REGISTER NOW!
